- 62.5 mg - Bosentas;
- 125 mg - Bosentas.
Without a Prescription
Bosentas is prescribed for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO Class III or
IV symptoms, to improve exercise ability and decrease the rate of clinical worsening.
Bosentas treatment should be initiated at a dose of 62.5 mg for 4 weeks and then increased to the maintenance dose of 125 mg.
Doses above 125 mg did not appear to confer additional benefit sufficient to offset the increased risk of liver injury.
Tablets should be administered morning and evening with or without food.
Treatment should be stopped and re-introduction of Bosentas should not be considered. There is no experience with re-introduction of Bosentas in these circumstances.
If Bosentas is re-introduced Bosentas should be at the starting dose; aminotransferase levels should be checked within 3 days and thereafter according to the recommendations above.
- Hypersensitivity: Bosentas is also contraindicated in patients who are hypersensitive to Bosentas or any component of the medication.
- Glyburide: An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with Bosentas. Therefore co-administration of glyburide and Bosentas is contraindicated.
- Cyclosporine A: Co-administration of cyclosporine A and Bosentas resulted in markedly increased plasma concentrations of Bosentas. Therefore, concomitant use of Bosentas and cyclosporine A is contraindicated.
Blister pack of 10 tablets